Merck Serono and Sysmex Inostics Announce First Liquid Biopsy RAS Biomarker Testing Center Opens: Important Milestone fo

About Merck Serono

Merck Serono is the biopharmaceutical business of Merck. With headquarters in Darmstadt, Germany, Merck Serono offers leading brands in 150 countries to help patients with cancer, multiple sclerosis, infertility, endocrine and metabolic disorders as well as cardiovascular diseases. In the United States and Canada, EMD Serono operates as a separately incorporated subsidiary of Merck Serono.

Merck Serono discovers, develops, manufactures and markets prescription medicines of both chemical and biological origin in specialist indications. We have an enduring commitment to deliver novel therapies in our core focus areas of neurology, oncology, immuno-oncology and immunology.

For more information, please visit http://www.merckserono.com

All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

Merck is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses - Merck Serono, Consumer Health, Allergopharma, Biosimilars, Merck Millipore and Performance Materials - and generated total revenues of EUR 11.1 billion in 2013. Around 39,000 Merck employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges. Merck is the world's oldest pharmaceutical and chemical company - since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day. Merck, Darmstadt, Germany, holds the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company operates as EMD Serono, EMD Millipore and EMD Performance Materials.

References

1. Diaz LA Jr and Bardelli A. J Clin Oncol 2014;32(6):579-86.

2. Vaughn CP, et al. Genes Chromosomes Cancer 2011;50(5):307-12.

3. Douillard J-Y, et al. N Engl J Med 2013;369(11):1023-34.

4. Schwartzberg LS, et al. J Clin Oncol 2014;32(21):2240-7.

5. Bokemeyer C, et al. Oral presentation at the 2014 American Society of Clinical Oncology Annual Meeting, May 30-June 3, 2014. Abstract No:3505.

6. Stintzing S, et al. Oral presentation at the 2014 European Society of Medical Oncology Annual Meeting, September 26-30, 2014. Abstract No:LBA11.

7. Van Cutsem E, et al. J Clin Oncol 2015;pii: JCO.2014.59.4812.

8. Erbitux(R) (cetuximab) SmPC, 2014. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_... . Last accessed February 2015.

9. Vectibix(R) (panitumumab) SmPC, 2014. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_... . Last accessed February 2015.

10. Ferlay J, et al. Int J Cancer 2015;136(5):E359-86.

For more information on Merck Serono in oncology and immuno-oncology, please visit: http://www.globalcancernews.com.

CONTACT: Your Contact: Cornelia Bartels, Phone +49-6151-72-3890